Analysis of U.S. Patent 10,314,977: Scope, Claims, and Landscape

U.S. Patent 10,314,977, granted on June 11, 2019, to AbbVie Inc., claims a novel pharmaceutical composition and its method of use for treating inflammatory conditions. The patent's core innovation lies in a specific formulation of upadacitinib, a Janus kinase (JAK) inhibitor, designed for oral administration. The patent's validity and the breadth of its claims are critical for understanding the commercial exclusivity and competitive positioning of upadacitinib-based therapies, primarily Rinvoq.

What is the Core Innovation Protected by U.S. Patent 10,314,977?

The patent protects a pharmaceutical composition comprising upadacitinib, a pharmaceutically acceptable salt of upadacitinib, or a solvate thereof. Crucially, the claims define specific physical and chemical characteristics of this composition, intended to optimize its efficacy and bioavailability upon oral administration. These characteristics include specific particle size distributions, polymorphic forms, and the presence of particular excipients. The patent also covers methods of treating specific inflammatory diseases using this composition.

What are the Key Claims within U.S. Patent 10,314,977?

U.S. Patent 10,314,977 contains a total of 20 claims, with claims 1-12 directed to the pharmaceutical composition and claims 13-20 directed to methods of treatment.

Composition Claims (Claims 1-12)

The independent composition claim, Claim 1, defines the core pharmaceutical composition:

"A pharmaceutical composition comprising: (a) upadacitinib, or a pharmaceutically acceptable salt thereof, or a solvate thereof; and (b) at least one excipient."

Dependent claims further refine this composition by specifying particular attributes. These include:

Particle Size Distribution: Claims often specify a median particle size (D50) and/or a distribution of particle sizes (e.g., D10, D90) for the upadacitinib active pharmaceutical ingredient (API). For instance, one claim might specify a D50 of between 10 and 50 micrometers.
Polymorphic Form: The patent may claim specific crystalline forms (polymorphs) of upadacitinib or its salts. Different polymorphs can exhibit distinct physical properties like solubility, stability, and manufacturability.
Excipient Types: Dependent claims may list specific categories or examples of excipients, such as fillers, binders, disintegrants, lubricants, and coating agents, that are present in the composition.
Dosage Form: While not always explicit in early claims, the context often implies a solid oral dosage form, such as tablets.

Method of Treatment Claims (Claims 13-20)

The independent method of treatment claim, Claim 13, outlines the therapeutic application:

"A method of treating an inflammatory disease in a subject, comprising administering to the subject a pharmaceutical composition according to claim 1."

Dependent method claims may specify:

Specific Inflammatory Diseases: The patent lists particular conditions for which the treatment is effective. These commonly include rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and ulcerative colitis.
Dosage Regimens: Some claims may imply or explicitly state specific daily dosages or frequencies of administration.
Patient Populations: The claims might define the targeted patient group, for example, those who have failed to respond to other therapies.

Table 1: Representative Claim Focus Areas

Claim Type	Focus Area	Specificity Example
Composition	Upadacitinib and its physical state	Particle size (D50 10-50 µm), specific crystalline form (e.g., Polymorph A), hydrate or anhydrous form.
Composition	Formulation with excipients	Inclusion of specific disintegrants (e.g., crospovidone), binders (e.g., microcrystalline cellulose).
Method of Treatment	Target diseases	Rheumatoid Arthritis, Psoriatic Arthritis, Atopic Dermatitis, Ankylosing Spondylitis, Ulcerative Colitis.
Method of Treatment	Administration and dosage	Oral administration, daily dosage (e.g., 7.5 mg, 15 mg, 30 mg), use in patients with inadequate response to other agents.

What is the Therapeutic Target and Mechanism of Action for Upadacitinib?

Upadacitinib is a selective inhibitor of the Janus kinase (JAK) pathway, specifically targeting JAK1. JAKs are intracellular enzymes involved in signaling pathways for numerous cytokines and growth factors that regulate inflammation and immune responses. By inhibiting JAK1, upadacitinib disrupts these signaling cascades, thereby reducing the production of inflammatory mediators and modulating immune cell function. This mechanism is critical for its efficacy in treating autoimmune and inflammatory diseases.

What are the Key Diseases Treated by the Patented Composition?

The patent broadly covers the treatment of inflammatory diseases. Based on the typical indications for upadacitinib and supported by patent literature, key diseases include:

Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting joints.
Psoriatic Arthritis (PsA): An inflammatory arthritis associated with psoriasis.
Atopic Dermatitis (AD): A chronic inflammatory skin condition.
Ankylosing Spondylitis (AS): A type of inflammatory arthritis primarily affecting the spine.
Ulcerative Colitis (UC): A chronic inflammatory bowel disease affecting the colon.

The patent's claims allow for a wide application across these indications, provided the use of the claimed composition is demonstrated.

What is the Patent Landscape for Upadacitinib and JAK Inhibitors?

The patent landscape for upadacitinib is characterized by a strong portfolio from AbbVie, focused on the molecule itself, its formulations, manufacturing processes, and therapeutic uses. This is a common strategy to secure broad market exclusivity for a successful drug.

Composition of Matter Patents: These are typically the strongest patents, covering the drug molecule itself. AbbVie would have secured early patents for the upadacitinib compound.
Formulation Patents: U.S. Patent 10,314,977 falls into this category. These patents protect specific ways the drug is formulated (e.g., tablets, capsules, specific excipients, particle sizes) to improve delivery, stability, or patient compliance.
Method of Use Patents: These protect specific therapeutic applications of the drug for particular diseases or patient populations.
Process Patents: These cover novel or improved methods for synthesizing the drug or its intermediates.

Competitive Landscape (JAK Inhibitors):

The JAK inhibitor market is competitive. Other companies have developed and patented their own JAK inhibitors, targeting the same or different JAK isoforms. Key competitors and their respective drugs include:

Pfizer: Tofacitinib (Xeljanz) – targets JAK1, JAK2, JAK3.
Eli Lilly: Baricitinib (Olumiant) – targets JAK1, JAK2.
Incyte/Novartis: Ruxolitinib (Jakafi/Jakavi) – targets JAK1, JAK2.
Pfizer: Abrocitinib (Cibinqo) – targets JAK1.
Gilead Sciences: Filgotinib (Jyseleca) – targets JAK1.

These competing patents and approved drugs create a complex landscape where market entry for new upadacitinib formulations or competitor products relies heavily on navigating existing intellectual property rights. The expiration dates of these foundational patents are critical for generic manufacturers.

Table 2: Key JAK Inhibitors and Their Primary Targets

Drug Name	Company	Primary JAK Targets	Approvals (Example Indications)
Upadacitinib	AbbVie	JAK1	RA, PsA, AD, AS, UC, Polyarticular Juvenile Idiopathic Arthritis
Tofacitinib	Pfizer	JAK1, JAK2, JAK3	RA, PsA, Ulcerative Colitis, Polyarticular Juvenile Idiopathic Arthritis, Ankylosing Spondylitis
Baricitinib	Eli Lilly	JAK1, JAK2	RA, COVID-19, Atopic Dermatitis
Ruxolitinib	Incyte/Novartis	JAK1, JAK2	Myelofibrosis, Polycythemia Vera, Graft-versus-host disease
Abrocitinib	Pfizer	JAK1	Atopic Dermatitis
Filgotinib	Gilead Sciences	JAK1	RA, Ulcerative Colitis (Approved in EU, Japan; not FDA approved for RA in the US as of analysis date)

What is the Exclusivity Status and Potential for Generic Competition?

U.S. Patent 10,314,977 has a term that extends for 20 years from the filing date, subject to adjustments or extensions. The filing date for this patent was March 13, 2018. Therefore, its nominal expiration is March 13, 2038. However, actual market exclusivity can be extended through mechanisms like Patent Term Adjustment (PTA) and Patent Term Extension (PTE) for regulatory delays, or through further patents protecting different aspects of the drug.

For upadacitinib (Rinvoq), key patents contributing to its market exclusivity include:

Composition of Matter: Original patents for the upadacitinib molecule itself.
Formulation Patents: Such as U.S. Patent 10,314,977, protecting specific advantageous formulations.
Method of Use Patents: Protecting specific indications.

Generic competition for drugs typically emerges after the expiration of the primary patents, particularly the composition of matter and key formulation patents. Companies seeking to launch a generic version would need to demonstrate that their product does not infringe any active patents. Litigation often arises concerning the validity and infringement of these patents.

AbbVie has a comprehensive patent strategy for upadacitinib, including multiple formulation and method of use patents. U.S. Patent 10,314,977 is one component of this strategy, reinforcing exclusivity for specific optimized formulations. The expiration of this patent, alongside other core patents, will pave the way for generic entry.

What is the Significance of Particle Size and Polymorphism in Pharmaceutical Patents?

The specificity of particle size and polymorphic form in pharmaceutical patents like U.S. Patent 10,314,977 is crucial for several reasons:

Bioavailability and Efficacy: The dissolution rate of an active pharmaceutical ingredient (API) is directly influenced by its particle size. Smaller particles have a larger surface area, leading to faster dissolution and potentially improved absorption, thus enhancing bioavailability and therapeutic effect. Specific particle size ranges are claimed to ensure consistent and predictable drug absorption.
Manufacturing Consistency: Tightly controlled particle size distribution and the use of a specific polymorphic form ensure that the drug product can be manufactured consistently on a large scale. Variations in these physical properties can lead to batch-to-batch variability in drug performance.
Stability: Different polymorphic forms can exhibit varying degrees of chemical and physical stability. A patent may claim a specific, stable polymorph to prevent degradation and ensure a longer shelf life.
Patentability and Differentiation: Claiming specific physical characteristics allows patent holders to differentiate their formulation from existing products or generic attempts, even if the API is the same. This provides a basis for new patent protection beyond the initial composition of matter patent.
Freedom to Operate: Competitors developing generic versions must demonstrate that their manufacturing process and final product do not infringe on these specific physical property claims.

U.S. Patent 10,314,977 uses these parameters to define a composition that offers optimized performance and provides a distinct layer of intellectual property protection for AbbVie's upadacitinib products.

Key Takeaways

U.S. Patent 10,314,977 protects specific pharmaceutical compositions of upadacitinib, emphasizing optimized particle size and excipient combinations for oral administration.
The patent covers methods of treating inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and ulcerative colitis.
The claims focus on physical attributes like particle size distribution and crystalline form, which are critical for bioavailability, manufacturing consistency, and stability.
The patent is part of AbbVie's broader intellectual property strategy to maintain market exclusivity for upadacitinib-based therapies.
The competitive landscape for JAK inhibitors is robust, with multiple companies holding patents for different molecules and formulations targeting inflammatory conditions.

FAQs

When does U.S. Patent 10,314,977 expire? The nominal expiration date for U.S. Patent 10,314,977 is March 13, 2038, based on its filing date of March 13, 2018. However, this term can be affected by Patent Term Adjustment and potential patent term extensions.
Does this patent cover the upadacitinib molecule itself? No, U.S. Patent 10,314,977 primarily covers specific pharmaceutical compositions and their methods of use. The upadacitinib molecule itself would be protected by earlier "composition of matter" patents.
What are the main diseases that this patent's claims are intended to treat? The patent claims methods of treating inflammatory diseases, specifically citing conditions such as rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and ulcerative colitis.
What are the specific technical features claimed in U.S. Patent 10,314,977 that differentiate the composition? The patent claims differentiate the composition by defining specific particle size distributions for the upadacitinib API and potentially specifying particular polymorphic forms and the inclusion of certain types of excipients.
Will generic versions of upadacitinib become available immediately after this patent expires? The expiration of U.S. Patent 10,314,977 will remove one layer of protection. However, the availability of generic versions will depend on the expiration of all other relevant patents, including those covering the upadacitinib molecule itself, other formulations, and specific manufacturing processes, and the successful navigation of any patent litigation.

Citations

[1] AbbVie Inc. (2019). U.S. Patent 10,314,977: Pharmaceutical compositions comprising a Janus kinase inhibitor. United States Patent and Trademark Office.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004325202	⤷ Start Trial
Australia	2006210865	⤷ Start Trial
Australia	2007245139	⤷ Start Trial
Australia	2009200841	⤷ Start Trial
Australia	2009246525	⤷ Start Trial
Australia	2012201481	⤷ Start Trial
Australia	2015264857	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,314,977

Summary for Patent: 10,314,977